Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
Sunshine Biopharma (NASDAQ:SBFM) has expanded its product line through its Canadian subsidiary, Nora Pharma, by launching two new generic prescription drugs: Olanzapine and Olanzapine ODT. Olanzapine, a generic version of Zyprexa, is used for treating schizophrenia, bipolar I disorder, and treatment-resistant depression when combined with other medications.
The products will be available in the Canadian market in various strengths: Olanzapine in bottles of 100 tablets (2.5mg to 20mg) and Olanzapine ODT in blisters of 30 tablets (5mg to 20mg). The launch aligns with market growth expectations driven by increasing mental health issues, with approximately 14 million adults reporting serious mental illness in 2021.
The Canadian generic drugs market, currently valued at $9.4 billion, is projected to reach $19.2 billion by 2032.
Sunshine Biopharma (NASDAQ:SBFM) ha ampliato la sua linea di prodotti attraverso la sua filiale canadese, Nora Pharma, lanciando due nuovi farmaci generici: Olanzapina e Olanzapina ODT. L'Olanzapina, versione generica dello Zyprexa, è utilizzata per il trattamento della schizofrenia, del disturbo bipolare di tipo I e della depressione resistente ai trattamenti quando combinata con altri farmaci.
I prodotti saranno disponibili sul mercato canadese in vari dosaggi: Olanzapina in flaconi da 100 compresse (2,5mg a 20mg) e Olanzapina ODT in blister da 30 compresse (5mg a 20mg). Il lancio è in linea con le aspettative di crescita del mercato, alimentato dall'aumento dei problemi di salute mentale, con circa 14 milioni di adulti che nel 2021 hanno riportato gravi malattie mentali.
Il mercato canadese dei farmaci generici, attualmente valutato $9,4 miliardi, è previsto raggiunga $19,2 miliardi entro il 2032.
Sunshine Biopharma (NASDAQ:SBFM) ha ampliado su línea de productos a través de su filial canadiense, Nora Pharma, al lanzar dos nuevos medicamentos genéricos: Olanzapina y Olanzapina ODT. La Olanzapina, versión genérica de Zyprexa, se utiliza para tratar la esquizofrenia, el trastorno bipolar tipo I y la depresión resistente al tratamiento cuando se combina con otros medicamentos.
Los productos estarán disponibles en el mercado canadiense en varias concentraciones: Olanzapina en frascos de 100 tabletas (2.5mg a 20mg) y Olanzapina ODT en blísteres de 30 tabletas (5mg a 20mg). El lanzamiento se alinea con las expectativas de crecimiento del mercado impulsadas por el aumento de problemas de salud mental, con aproximadamente 14 millones de adultos reportando enfermedades mentales graves en 2021.
El mercado canadiense de medicamentos genéricos, actualmente valorado en $9.4 mil millones, se proyecta que alcanzará $19.2 mil millones para 2032.
Sunshine Biopharma (NASDAQ:SBFM)는 캐나다 자회사인 Nora Pharma를 통해 올란자핀 및 올란자핀 ODT라는 두 가지 새로운 제네릭 처방약을 출시하며 제품 라인을 확장했습니다. 올란자핀은 Zyprexa의 제네릭 버전으로, 조현병, 양극성 장애 I형 및 다른 약물과 함께 사용할 때 치료 저항성 우울증 치료에 사용됩니다.
이 제품들은 캐나다 시장에서 다양한 강도로 제공됩니다: 올란자핀은 100정(2.5mg ~ 20mg) 병에, 올란자핀 ODT는 30정(5mg ~ 20mg) 블리스터에 포장되어 판매됩니다. 이 출시는 정신 건강 문제 증가에 따른 시장 성장 기대에 부합하며, 2021년에는 약 1400만 명의 성인이 심각한 정신질환을 보고했습니다.
현재 $9.4억으로 평가되는 캐나다 제네릭 약물 시장은 2032년까지 $19.2억에 달할 것으로 예상됩니다.
Sunshine Biopharma (NASDAQ:SBFM) a élargi sa gamme de produits par l'intermédiaire de sa filiale canadienne, Nora Pharma, en lançant deux nouveaux médicaments génériques sur ordonnance : Olanzapine et Olanzapine ODT. L'Olanzapine, version générique du Zyprexa, est utilisée pour traiter la schizophrénie, le trouble bipolaire de type I et la dépression résistante au traitement lorsqu'elle est associée à d'autres médicaments.
Les produits seront disponibles sur le marché canadien dans différentes dosages : Olanzapine en flacons de 100 comprimés (2,5 mg à 20 mg) et Olanzapine ODT en blisters de 30 comprimés (5 mg à 20 mg). Le lancement s'inscrit dans les attentes de croissance du marché, soutenues par l'augmentation des problèmes de santé mentale, avec environ 14 millions d'adultes déclarant une maladie mentale grave en 2021.
Le marché canadien des médicaments génériques, actuellement évalué à 9,4 milliards de dollars, devrait atteindre 19,2 milliards de dollars d'ici 2032.
Sunshine Biopharma (NASDAQ:SBFM) hat seine Produktlinie über seine kanadische Tochtergesellschaft, Nora Pharma, erweitert, indem es zwei neue generische rezeptpflichtige Medikamente eingeführt hat: Olanzapin und Olanzapin ODT. Olanzapin, eine generische Version von Zyprexa, wird zur Behandlung von Schizophrenie, bipolaren Störungen I und behandlungsresistenter Depression eingesetzt, wenn es mit anderen Medikamenten kombiniert wird.
Die Produkte werden auf dem kanadischen Markt in verschiedenen Stärken erhältlich sein: Olanzapin in Flaschen mit 100 Tabletten (2,5 mg bis 20 mg) und Olanzapin ODT in Blistern mit 30 Tabletten (5 mg bis 20 mg). Der Launch passt zu den Marktwachstumsprognosen, die durch steigende psychische Gesundheitsprobleme getrieben werden, wobei 2021 etwa 14 Millionen Erwachsene eine ernsthafte psychische Erkrankung meldeten.
Der kanadische Markt für generische Medikamente, der derzeit mit 9,4 Milliarden USD bewertet wird, wird voraussichtlich bis 2032 19,2 Milliarden USD erreichen.
- Entry into growing mental health medication market with two new generic drug products
- Expansion of product portfolio to 69 generic prescription drugs
- Targeting Canadian generic drugs market with projected growth from $9.4B to $19.2B by 2032
- None.
Insights
The expansion into Olanzapine and Olanzapine ODT represents a strategic move into a growing mental health therapeutics market. The Canadian generic drugs market's projected growth from
Olanzapine's multi-indication approval for schizophrenia, bipolar disorder and treatment-resistant depression, particularly when used in combination therapies, positions it as a versatile product in the mental health space. The availability in multiple dosage forms (regular and ODT) and strengths enhances market penetration potential by addressing different patient needs. However, the company's relatively small market cap of
The timing of this product launch aligns perfectly with increasing mental health awareness and treatment needs. The reported
The combination therapy possibilities with Lithium, Valproate and Fluoxetine expand the product's utility across multiple treatment protocols. For the average person, think of this like having a Swiss Army knife in mental health treatment - one tool that can be used in multiple ways depending on the specific needs of each patient. The growing aging population and increased mental health awareness suggest sustained demand growth for these products.
FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs.
The newly launched drugs are Olanzapine and Olanzapine ODT. Olanzapine is a generic version of Zyprexa®. Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders. Olanzapine is also indicated for the acute treatment of manic or mixed episodes of bipolar I disorder. Nora Pharma's Olanzapine is available in bottles of 100 tablets for the Canadian market in strengths of 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg. Nora Pharma's Olanzapine ODT (Orally Disintegrating Tablets) is available for the Canadian market in strengths of 5mg, 10mg, 15mg and 20mg in blisters of 30 tablets.
In addition to its use as a monotherapy, Olanzapine is used in combination with Lithium or Valproate for treatment of depressive episodes of bipolar I disorder and in combination with Fluoxetine for treatment-resistant depression.
The olanzapine market is expected to see steady growth in the coming years. The projected increase in emotional illness and mental health issues is set to drive the expansion. In 2023, a report from the Substance Abuse and Mental Health Services Administration (an agency within the U.S. Department of Health and Human Services) revealed a staggering statistic of
"We continue to strengthen our presence in the Canadian generic drugs market, currently estimated to be at
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 69 generic prescription drugs on the market in Canada and 20 additional drugs scheduled to be launched in 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.
In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
What new generic drugs did Sunshine Biopharma (SBFM) launch in January 2025?
What is the total number of generic prescription drugs in SBFM's portfolio after the new launches?
What are the available strengths for SBFM's Olanzapine in the Canadian market?
What is the projected size of the Canadian generic drugs market that SBFM is targeting by 2032?
What medical conditions can SBFM's new Olanzapine drug treat?
